A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens
Phase of Trial: Phase III
Latest Information Update: 03 Feb 2019
At a glance
- Drugs Cefiderocol (Primary) ; Linezolid; Meropenem
- Indications Gram-negative infections; Nosocomial pneumonia
- Focus Registrational; Therapeutic Use
- Acronyms APEKS-NP
- Sponsors Shionogi
- 03 Jan 2019 Planned End Date changed from 1 Feb 2019 to 5 Jul 2019.
- 03 Jan 2019 Planned primary completion date changed from 1 Jan 2019 to 21 Jun 2019.
- 23 May 2018 Study design presented at the 114th International Conference of the American Thoracic Society